RO
ROIV
ROIV What Roivant Sciences promised, and what happened
Guidance
What management said, and what became of it
10 of 11 judged targets kept · 10 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Brepocitinib cutaneous sarcoidosis (CS) Phase III trial initiation | Starting a Phase III study this calendar year | Dec 2025 | the initiation of the cutaneous sarcoidosis Phase III study is a pretty exciting event. It's a little bit ahead of schedule | Achieved |
| Brepocitinib commercial launch in dermatomyositis (DM) | Launch by the end of September (assuming FDA approval as expected) | Mar 2026 | We've got brepocitinib expected to launch by the end of September. Obviously, we got priority review and our PDUFA date, as we said, is this quarter. | On Track |
| Batoclimab TED (thyroid eye disease) study data readout | Data coming next calendar year | Sep 2024 | we announced the failure of the bitokamab studies in TED | Missed |
The full ledger
Open Roivant Sciences’s full ledger
A free account opens 5 company ledgers a month. All 21 tracked commitments, with each call’s wording and source.
The rest of the ledger
Pro opens all 21 tracked commitments for Roivant Sciences
Above is what the last two calls moved. Pro adds every quarter's revision, the source quote behind each one, and the topics management has stopped answering.